Fotemustine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino} ethyl)phosphonate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
92118-27-9  | |
| L01AD05 | |
| PubChem | CID 104799 |
| DrugBank |
DB04106 |
| ChemSpider |
94600  |
| UNII |
GQ7JL9P5I2 |
| KEGG |
D07255 |
| ChEMBL |
CHEMBL549386 |
| Chemical data | |
| Formula | C9H19ClN3O5P |
| 315.691 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).
External links
- ↑ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study" 22 (6). pp. 1118–25. doi:10.1200/JCO.2004.04.165. PMID 15020614.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||